Oncolytics Biotech Inc T.ONC

ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

[Noteable]

October 23, 2023  - 7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25%

The ORR of 62% is close to triple the average ORR in mPC which have been reported in historical control trials, suggesting that pelareorep synergizes with PD-L1 inhibitors and standard-of-care chemotherapy in patients with advanced/metastatic pancreatic ductal adenocarcinoma.

By comparison in October 2022, the FDA approved J&J multiple myeloma cancer drug with an ORR of 61.8% at 7.2 months and a duration of response (DOR) of 66.5% at 9 months. 

The PDAC arm of ONCYs GOBLET study showed an overall response rate (ORR) of 62%, median progression-free survival of 7.2 months (mPFS), and an interim median overall survival of 10.6 months (iOS). 

Tumour-infiltrating lymphocytes (TILs) are considered crucial in anti-tumour immunity. Accordingly, the presence of TILs contains prognostic and predictive value. 

The interaction between cancer and immune cells in the tumour microenvironment (TME) is thought to be crucial for the control of the development and progression of malignant tumours. Accordingly, tumour-infiltrating lymphocytes (TILs) have been identified in primary tumour tissue, tumour-bearing lymph nodes and metastases of numerous cancer types. TILs are defined as lymphocytes within and around cancer cells and have been associated with a survival benefit

https://www.nature.com/articles/s41416-022-02119-4

Overall (TCR) TILS is a strong prognostic biomarker in an early stage setting. ONCYs GOBLET study further confirmed T cell diversity and TCR clonality as markers of ICIs efficacy in combination with pelareorep.

ONCYs TCR (TiLs) biomarker data as been further validated,as outlined in ONCYs press release:

https://www.sciencedirect.com/science/article/pii/S0923753421021852

T-Cell Populations: Analysis of changes of T-cell clones and tumor-infiltrating lymphocytes (TILs) showed:

• Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones
• A correlation between the expansion in the blood of TIL-specific clones and tumor response

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma

https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=35680394